{"brief_title": "Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD", "brief_summary": "To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.", "condition": "Acute Graft Versus Host Disease", "intervention_type": "Drug", "intervention_name": "pentostatin for injection", "criteria": "Inclusion: - Patients 6 months of age with grade 2 GVHD that is steroid-refractory - Must be engrafted with ANC 1000/mL, may still be transfusion dependent for platelets and PRBC - Time post stem cell infusion < 100 days - Written informed consent - Must have adequate renal function (creatinine clearance 40 mL/min/1.73 m2 Exclusion: - Post-transplant lymphoproliferative disease - Uncontrolled infection - Mental illness or other condition preventing full cooperation with the treatment and monitoring requirements of the study - ATG within the previous 14 days - Other immunosuppressive agents (including monoclonal antibodies) when initiated within the previous 7 days.", "gender": "All", "minimum_age": "6 Months", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00032773.xml"}